Antitumor effects of HSV-TK–engineered donor lymphocytes after allogeneic stem-cell transplantation

Ciceri, Fabio; Bonini, Chiara; Marktel, Sarah; Zappone, Elisabetta; Servida, Paolo; Bernardi, Massimo; Pescarollo, Alessandra; Bondanza, Attilio; Peccatori, Jacopo; Rossini, Silvano; Magnani, Zulma; Salomoni, Monica; Benati, Claudia; Ponzoni, Maurilio; Callegaro, Luciano; Corradini, Paolo; Bregni, Marco; Traversari, Catia; Bordignon, Claudio

doi:10.1182/blood-2006-05-023416

Cited by 157 publications

(137 citation statements)

References 50 publications

Supporting

Mentioning

132

Contrasting

Order By: Relevance

“…59 The investigators at St Raffaele Hospital of Milano have also achieved encouraging results with the post-transplant infusion of T-cells transfected with the thymidine kinase suicide gene, which allows an early and effective immune restoration. 60 These experiences support the investigation of this transplantation modality in patients who lack an HLA-compatible family donor and need an allogeneic procedure on a short-term basis. There are no studies comparing URD SCT and haploidentical transplantation in patients with AML.…”

Section: Urd Vs Haploidentical Transplantsmentioning

confidence: 84%

Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia

Sierra

Martino

Sánchez

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Transplantation from unrelated donors (URD) is increasingly being used as treatment for hematological malignancies, including acute myeloid leukemia (AML). This increase is the consequence of the availability of more than 11 million URD volunteers and the more efficient donor search process in the recent years. Median time to identify a suitable URD is now 2 months. More than 50% of Caucasian patients have an human leukocyte antigen (HLA)-allele donor match and a one-antigen or allele HLA-mismatched donor may also be acceptable. Complications of URD transplants are particularly frequent and severe, with long-term OS in the registries being 10-20% inferior to HLA-identical sibling transplantation. High resolution DNA techniques for donor and recipient HLA matching have contributed to the survival in experienced centres after unrelated donor SCT approaching that achieved with sibling donors. The introduction of reduced intensity conditioning (RIC) has extended URD transplants to elderly and/or debilitated patients with AML. With this approach, TRM decreases, although graftversus-host disease-related morbidity and mortality remain a problem. Despite this complication, results after URD transplantation in this age group seem better than those achieved with chemotherapy and/or autologous transplantation. To confirm this possibility, prospective multicenter comparisons of URD transplants after RIC with other treatment options for elderly AML patients have recently been started.

show abstract

Section: Urd Vs Haploidentical Transplantsmentioning

confidence: 84%

Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia

Sierra

Martino

Sánchez

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…GvT activity was observed and directly correlated with in vivo expansion of TK lymphocytes. 48 Long-term persistence of polyclonal TK cells was observed in several trials, 49 suggesting that TK cells could mediate long-term immunosurveillance against tumors. In a phase I-II multicenter trial, TK cells were infused to patients with high-risk leukemia after haplo-SCT, to induce early immune reconstitution and promote GvT, while selectively controlling GvHD.…”

Section: The Adoptive Transfer Of Selected Antigen-specific Lymphocytmentioning

confidence: 99%

Progress and prospects: graft-versus-host disease

et al. 2010

View full text Add to dashboard Cite

“…Bordignon's group used the Herpes simplex virus thymidine kinase gene (HSVtk) as a suicide gene, allowing in vivo specific killing of vector-containing cells via administration the relatively nontoxic drug ganciclovir. Importantly, this strategy has proved to be effective in treating or to ameliorate GvHD in several Phase I/II clinical trials (Bonini et al, 1997;Tiberghien et al, 1997;Ciceri et al, 2007;Qasim et al, 2007).…”

Section: Marking T Cellsmentioning

confidence: 99%